Combination of Anti-programmed Cell Death Protein 1 and Antiangiogenesis Displaying a Response Disparity between Pulmonary and Nonpulmonary Metastases
Targeting the vascular endothelial growth factor-mediated immune suppression is a strategy to overcome the resistance of anti-programmed cell death protein 1/programmed death-ligand 1 (anti-PD-1/PD-L1) therapy. Here, we present two cases, including one case with leiomyosarcoma and the other one with...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2023-10-01
|
| Series: | Journal of Cancer Research and Practice |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/ejcrp.eJCRP-D-23-00016 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | Targeting the vascular endothelial growth factor-mediated immune suppression is a strategy to overcome the resistance of anti-programmed cell death protein 1/programmed death-ligand 1 (anti-PD-1/PD-L1) therapy. Here, we present two cases, including one case with leiomyosarcoma and the other one with microsatellite-stable colorectal cancer, receiving the combination of pembrolizumab and lenvatinib as salvage treatment. Both cases demonstrated a significant response in lung metastases; however, the nonpulmonary metastases progressed. These findings suggest that lung metastasis might have a distinct tumor immune microenvironment, and further studies to investigate the efficacy of PD-1/PD-L1-based combination therapy in patients with lung-limited metastases are warranted. |
|---|---|
| ISSN: | 2311-3006 |